aluates Reports

$ 0.0

Automative

Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Research Report 2025

Published Date: June 2025

Report Code: QYRE-Auto-15A13655

Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Research Report 2023

BUY CHAPTERS

Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Research Report 2025

Code: QYRE-Auto-15A13655

Report

June 2025

Pages:78

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novartis

Pfizer Inc

Fresenius Kabi

Teva Pharmaceuticals

Sun Pharma

Hutchison China MediTech Limited

Exelixis Inc

Tarveda Therapeutics

Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market

The global market for Gastroenteropancreatic Neuroendocrine Tumor Therapeutics was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gastroenteropancreatic Neuroendocrine Tumor Therapeutics.

The Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Report

Report Metric	Details
Report Name	Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market
CAGR	5%
Segment by Type	Chemotherapy Peptide-Receptor Radionuclide Therapy Others
Segment by Application	Hospitals Clinics Ambulatory Surgical Centers Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals, Sun Pharma, Hutchison China MediTech Limited, Exelixis, Inc., Tarveda Therapeutics
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market report?

Ans: The main players in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market are Novartis, Pfizer, Fresenius Kabi, Teva Pharmaceuticals, Sun Pharma, Hutchison China MediTech Limited, Exelixis, Inc., Tarveda Therapeutics

What are the Application segmentation covered in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market report?

Ans: The Applications covered in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market report are Hospitals, Clinics, Ambulatory Surgical Centers, Others

What are the Type segmentation covered in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market report?

Ans: The Types covered in the Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market report are Chemotherapy, Peptide-Receptor Radionuclide Therapy, Others

Recommended Reports

GI & Pancreatic Oncology

Cancer Therapeutics Drugs

Tumor Diagnosis & Devices

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Chemotherapy

1.2.3 Peptide-Receptor Radionuclide Therapy

1.2.4 Others

1.3 Market by Application

1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Ambulatory Surgical Centers

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2020-2031)

2.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Region

2.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Region (2020-2025)

2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031)

2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Dynamics

2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Trends

2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers

2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges

2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue

3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2020-2025)

3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2020-2025)

3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue

3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio

3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024

3.5 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Head office and Area Served

3.6 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application

3.7 Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type

4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2020-2025)

4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031)

5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application

5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2020-2025)

5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)

6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)

6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)

7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)

7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)

8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025)

8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)

9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)

9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2020-2031)

10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025)

10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Novartis

11.1.1 Novartis Company Details

11.1.2 Novartis Business Overview

11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.1.5 Novartis Recent Development

11.2 Pfizer

11.2.1 Pfizer Company Details

11.2.2 Pfizer Business Overview

11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.2.5 Pfizer Recent Development

11.3 Fresenius Kabi

11.3.1 Fresenius Kabi Company Details

11.3.2 Fresenius Kabi Business Overview

11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.3.5 Fresenius Kabi Recent Development

11.4 Teva Pharmaceuticals

11.4.1 Teva Pharmaceuticals Company Details

11.4.2 Teva Pharmaceuticals Business Overview

11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.4.5 Teva Pharmaceuticals Recent Development

11.5 Sun Pharma

11.5.1 Sun Pharma Company Details

11.5.2 Sun Pharma Business Overview

11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.5.5 Sun Pharma Recent Development

11.6 Hutchison China MediTech Limited

11.6.1 Hutchison China MediTech Limited Company Details

11.6.2 Hutchison China MediTech Limited Business Overview

11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.6.5 Hutchison China MediTech Limited Recent Development

11.7 Exelixis, Inc.

11.7.1 Exelixis, Inc. Company Details

11.7.2 Exelixis, Inc. Business Overview

11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.7.5 Exelixis, Inc. Recent Development

11.8 Tarveda Therapeutics

11.8.1 Tarveda Therapeutics Company Details

11.8.2 Tarveda Therapeutics Business Overview

11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction

11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

11.8.5 Tarveda Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Novartis

Pfizer Inc

Fresenius Kabi

Teva Pharmaceuticals

Sun Pharma

Hutchison China MediTech Limited

Exelixis Inc

Tarveda Therapeutics

List of Tables

Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Chemotherapy

Table 3. Key Players of Peptide-Receptor Radionuclide Therapy

Table 4. Key Players of Others

Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2025)

Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2026-2031)

Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends

Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers

Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges

Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints

Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2020-2025) & (US$ Million)

Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players (2020-2025)

Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)

Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2024

Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2020-2025)

Table 20. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Headquarters and Area Served

Table 21. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Product and Application

Table 22. Global Key Players of Gastroenteropancreatic Neuroendocrine Tumor Therapeutics, Date of Enter into This Industry

Table 23. Mergers & Acquisitions, Expansion Plans

Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2020-2025) & (US$ Million)

Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2020-2025)

Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2026-2031)

Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2025) & (US$ Million)

Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2020-2025)

Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Application (2026-2031)

Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 35. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 36. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 37. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 38. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 39. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2020-2025) & (US$ Million)

Table 40. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2026-2031) & (US$ Million)

Table 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 42. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 43. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2020-2025) & (US$ Million)

Table 46. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2026-2031) & (US$ Million)

Table 47. Novartis Company Details

Table 48. Novartis Business Overview

Table 49. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 50. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 51. Novartis Recent Development

Table 52. Pfizer Company Details

Table 53. Pfizer Business Overview

Table 54. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 55. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 56. Pfizer Recent Development

Table 57. Fresenius Kabi Company Details

Table 58. Fresenius Kabi Business Overview

Table 59. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 60. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 61. Fresenius Kabi Recent Development

Table 62. Teva Pharmaceuticals Company Details

Table 63. Teva Pharmaceuticals Business Overview

Table 64. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 65. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 66. Teva Pharmaceuticals Recent Development

Table 67. Sun Pharma Company Details

Table 68. Sun Pharma Business Overview

Table 69. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 70. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 71. Sun Pharma Recent Development

Table 72. Hutchison China MediTech Limited Company Details

Table 73. Hutchison China MediTech Limited Business Overview

Table 74. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 75. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 76. Hutchison China MediTech Limited Recent Development

Table 77. Exelixis, Inc. Company Details

Table 78. Exelixis, Inc. Business Overview

Table 79. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 80. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 81. Exelixis, Inc. Recent Development

Table 82. Tarveda Therapeutics Company Details

Table 83. Tarveda Therapeutics Business Overview

Table 84. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product

Table 85. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025) & (US$ Million)

Table 86. Tarveda Therapeutics Recent Development

Table 87. Research Programs/Design for This Report

Table 88. Key Data Information from Secondary Sources

Table 89. Key Data Information from Primary Sources

Table 90. Authors List of This Report

List of Figures

Figure 1. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Picture

Figure 2. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2024 VS 2031

Figure 4. Chemotherapy Features

Figure 5. Peptide-Receptor Radionuclide Therapy Features

Figure 6. Others Features

Figure 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2020-2031) & (US$ Million)

Figure 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2024 VS 2031

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Ambulatory Surgical Centers Case Studies

Figure 12. Others Case Studies

Figure 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered

Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region: 2024 VS 2031

Figure 17. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2024

Figure 18. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2024)

Figure 19. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2024

Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)

Figure 22. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 24. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)

Figure 26. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Nordic Countries Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2020-2031)

Figure 34. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)

Figure 42. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Country (2020-2031)

Figure 46. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 50. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 51. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 52. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 53. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 54. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 55. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 56. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2020-2025)

Figure 57. Bottom-up and Top-down Approaches for This Report

Figure 58. Data Triangulation

Figure 59. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Neuroendocrine Carcinoma Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neuroendocrine Tumor NET Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Neuroendocrine Carcinoma Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Pancreatic Endocrine Tumor Drug Market Research Report 2025

Global Gastrointestinal Stromal Tumors Therapeutics Market Research Report 2025

Rare Endocrine Disorders Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Cancer Therapeutics and Biotherapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Solid Tumor Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Tumor Immunotherapy Market

Global Gastrointestinal Rare Diseases Treatment Market Research Report 2025

Prostate Cancer Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Next Generation Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gastric Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Intratumoral Cancer Therapies Market Research Report 2025

Global Gastrointestinal Stromal Tumor GIST Drug Market Research Report 2024

Global Pancreatic Cancer Therapeutics and Diagnostics Market Research Report 2024

Global Brain Tumor Diagnostics and Therapeutics Market Research Report 2024

Brain Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Gamma Delta T Cell Cancer Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

RELATED REPORTS

Global Hormonal Therapy for Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5L19798

Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Cancer Insurance Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28I6901

Thu Sep 11 00:00:00 UTC 2025

Add to Cart

Global Induced Myeloid Leukemia Cell Differentiation Protein Mcl 1 Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-22R9736

Wed Sep 10 00:00:00 UTC 2025

Add to Cart

Global Drugs for Differentiated Thyroid Cancer Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-29A2598

Tue Sep 09 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions